On August 11, 2026, EDAP TMS S.A. entered into an underwriting agreement for an underwritten public offering of 8,425,000 American Depositary Shares at a price of $4.75 per share. The closing of the offering is expected to occur on August 14, 2026. This funding will support the company’s ongoing development of urological therapies
Who to call at EDAP TMS, and when
A new round usually means EDAP TMS is about to hire and buy. The teams that reach out first get the meeting.
An alert the day EDAP TMS raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at EDAP TMS, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
EDAP TMS
Location
Lyon, Auvergne Rhône Alpes, France
About
EDAP TMS is a high-tech medical company listed on the Nasdaq (EDAP) which develops, manufactures and markets minimally invasive medical devices using ultrasound technology for various medical applications and offers a wide portfolio of complementary distribution products in urology.
By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion.
As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems.
EDAP TMS is listed on NASDAQ market in New York under ticker symbol “EDAP”.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment EDAP TMS raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LyonManufacturingBiotechnologyHealth CareMedicalMedical DeviceMedical Equipment Manufacturing